Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-17
2007-07-17
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C530S330000, C530S331000
Reexamination Certificate
active
10052386
ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5162500 (1992-11-01), Takeuchi et al.
patent: 5359138 (1994-10-01), Takeuchi et al.
patent: 5488067 (1996-01-01), Hanson
patent: 5496927 (1996-03-01), Kolb et al.
patent: 5514694 (1996-05-01), Powers et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5739002 (1998-04-01), De Francesco et al.
patent: 5763576 (1998-06-01), Powers
patent: 5843450 (1998-12-01), Dawson et al.
patent: 5843752 (1998-12-01), Dasmahapatra et al.
patent: 5849866 (1998-12-01), Kolb et al.
patent: 5854001 (1998-12-01), Casey et al.
patent: 6265380 (2001-07-01), Tung et al.
patent: 2362911 (2000-09-01), None
patent: 0 195 212 (1986-09-01), None
patent: 0 363 284 (1990-04-01), None
patent: 0 423 358 (1991-04-01), None
patent: 0 672 648 (1995-09-01), None
patent: 2778406 (1999-11-01), None
patent: 2 338 482 (1998-04-01), None
patent: 4-001140 (1992-01-01), None
patent: 04 149166 (1992-05-01), None
patent: WO-92/11850 (1992-07-01), None
patent: WO-94/00095 (1994-01-01), None
patent: WO-95/33764 (1995-12-01), None
patent: WO-96/40743 (1996-12-01), None
patent: WO-97/06804 (1997-02-01), None
patent: WO-97/31937 (1997-09-01), None
patent: WO-98/12308 (1998-03-01), None
patent: WO-98/13462 (1998-04-01), None
patent: WO-98/14181 (1998-04-01), None
patent: WO 98 17679 (1998-04-01), None
patent: WO-98/29435 (1998-07-01), None
patent: WO-98/37180 (1998-08-01), None
patent: WO-99/07733 (1999-02-01), None
patent: WO 99 07734 (1999-02-01), None
patent: WO-99/64442 (1999-12-01), None
patent: WO 00 52032 (2000-09-01), None
patent: WO 01 40262 (2001-06-01), None
patent: WO 01 74768 (2001-10-01), None
patent: WO00/05245 (2002-02-01), None
patent: WO-02/18369 (2002-03-01), None
Wei Han, et al., “alpha-Ketoamides, alpha ketoesters and alpha-diketones as HCV NS3 protease inhibitors”,Bioorangic&Medicinal Chemistry Letters, vol. 10, No. 8 (2000), pp. 711-713.
Llinas-Brunet Montse, et al, “Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease”,Bioorganic&Medicinal Chemistry Letters, vol. 8, No. 19, (1998), pp. 2719-2724.
Bartenschlager et al., Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase, Journal of Virology, Jan. 1995, vol. 69, No. 1, pp. 198-205.
Bennett et al., The Identification of a-Ketomides as Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase, Bioganic & Medicinal Chemistry Letters 11 (2001), pp. 355-357.
Bianchi et al., Synthetic Depsipeptide Substrates for the Assay of Human Hepatitis C Virus Protease, Analytical Biochemistry 237, 239-244 (1996).
Bouffard et al., An in Vitro Assay for Hepatitis C Virus NS3 Serine Proteinase, Virology 209, 52-59 (1995).
Cho et al., Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity, Journal of Virological Methods 65 (1997), 201-207.
D'Souza et al., In vitro cleavage of hepatitis C virus polyprotein substrattes by purified recombinant NS3 protease, Journal of General Virology (1995), 76, 1729-1736.
Filocamo et al., Cimeric Sindbis Viruses Dependent on the NS3 Protease of Hepatitis C Virus, Journal of Virology, Feb. 1997, p. 1417-1427.
Hahm et al., Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity, Virology 226, 318-326 (1996).
Hamatake et al., Estabilishment of an vitro assay to Characterize Hepatitis C Virus NS3-4A Protease Trans-Proceeding Activity, Intervirology 1996; 39:249-258.
Harbeson et al., Stereospecific Synthesis of Peptidyl a-Keto Amides as Inhibitors of Calpain, J. Med. Chem. 1994, 37,2918-2929.
Ito et al., Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus, J. Gen. Virol May 1996; 77 (Pt 5):1043-54.
Lu et al., Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unsual properties of the internal ribosomal entry site of hepatitis C virus, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 1412-1417, Feb. 1996.
Mizutani et al., Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2, Journal of Virology, Oct. 1996, p. 7219-7223.
Mizutani et al., Inhibition of Hepatitis C Virus Replication by Antisense Oligonucleotide in Culture Cells, Biochemical and Biophysical Research Communications, vol. 212, No. 3, 1995, pp. 906-911.
Mizutani et al., Long-Term Human T-Cell Culture System Supporting Hepatitis C Virus Replication, Biochemical and Biophysical Research Communications 227, 822-826 (1996).
Narjes et al., a-Ketoacids are Potent Slow Binding Inhibitors of the Hepatitis C Virus NS3 Protease, Biochemistry (2000), vol. 39, pp. 1849-1861.
Ogilvie et al., Peptidomimetic Inhibitors of the Human Cytomegalovirus Protease, J. Med. Chem. 1997, 40, 4113-4135.
Scarselli et al., GB Virus B and Hepatitis C Virus NS3 Serine Proteases Share Subtrate Specificity, Journal of Virology, Jul. 1997, p. 4985-4989.
Schechter et al., On the Size of the Active Site Proteases,Biochemical and Biophysical Research Communiations, vol. 27, No. 2, 1967.
Shimizu et al., Multicycle Infection of Hepatitis C Virus in Cell Culture and Inhibition by Alpha and Beta Interferons, Journal of Virology, Dec. 1994, p. 8406-8408.
Steinkuhler et al., Product Inhibition of the Hepatitis C Virus NS3 Protease, Biochemistry 1998, vol. 37, pp. 8899-8905.
Sudo et al., Establishment of an in vitro assay for screening hepatitis C virus protease inhibitors using high performance liquid chromatography, Antiviral Research 32 (1996), pp. 9-18.
Takeshita et al., An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus Proteinase, Analytical Biochemistry (1997), 274, pp. 242-246.
Taliani et al., A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates, Analytical Biochemistry 240 (1996), pp. 60-67.
Taremi et al., Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease, Protein Science (1998), 7:2143-2149.
Tong et al., Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease, Nature Structural Biology (1998), vol. 5., No. 9, pp. 819-826.
Tsuda et al., Poststatin, a New Inhibitor of Prolyl Endopeptidase, The Journal of Antibiotics (1996), vol. 49, No. 3, pp. 287-291.
Tsuda et al., Poststatin, a New Inhibitor of Prolyl Endopeptidase, The Journal of Antibiotics (1996), vol. 49, No. 9, pp. 890-899.
Urbani et al., Substrate Specificity of the Hepatitis C Virus Serine Protease NS3, Journal of Biological Chemistry (1997), Apr. 4 Issue, pp. 9204-9209.
Wang et al., Expression of HCV NS3 Protease and Detection of Its Activity in Mammalian Cells, 4th International Meeting on Hepatitis C Virus and Related Viruses, Molecular Virology and Pathogenesis, Mar. 6-10, 1997.
Wasserman et al., (Cyanomethylene) phosphoranes as Novel Carbonyl 1,1-Dipole Synthons: An Efficient Synthesis of a-Keto, Acids, Esters, and Amides, J. Org. Chem. (1994), vol. 59, pp. 4364-4366.
Zhang et al., Probing the Substrate Specificity of Hepatitis C Virus NS3 Serine Protease by Using Synthetic Peptides, Journal of Virology, Aug. 1997, pp. 6208-6213.
Suto M.J., et al: “Peptide Inhibitors of IKB Protease: Modification of the C-termini of Z-LLF-CHO”, Bioraganic & Medicinal Chemistry Letters, Oxford, GB, vol. 6, No. 24, Dec. 17, 1996.
Patel, D.V. et al, “Activated Ketone Based Inhibitors of Human Renin”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 36, No. 17, Aug. 1, 1993, pp. 2431-244
Arasappan Ashok
Bennett Frank
Bogen Stephane L.
Chan Tin-Yau
Chen Kevin X.
Dendreon Corporation
Kalyanaraman Palaiyur S.
Lerner David Littenberg Krumholz & Mentlik LLP
Mondesi Robert B.
Schering Corporation
LandOfFree
Peptides as NS3-serine protease inhibitors of hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides as NS3-serine protease inhibitors of hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides as NS3-serine protease inhibitors of hepatitis C virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819347